Download PDF
Homœopathic Links 2022; 35(04): 291-301
DOI: 10.1055/s-0042-1756381
Case Report

Homoeopathic Add-On Treatment in Schizophrenia—A Case Report

S. Karunakara Moorthi 
1   National Homoeopathy Research Institute in Mental Health, Kottayam, Kerala, India
,
P. Radhika
1   National Homoeopathy Research Institute in Mental Health, Kottayam, Kerala, India
,
Susu Pertin
1   National Homoeopathy Research Institute in Mental Health, Kottayam, Kerala, India
,
N. D. Mohan
1   National Homoeopathy Research Institute in Mental Health, Kottayam, Kerala, India
› Author Affiliations Funding No funding was received for the case report or the preparation of the manuscript.
› Further Information
    Permissions and Reprints

Abstract

Introduction Schizophrenia is a chronic disabling disease which requires lifelong treatment. Antipsychotics are the mainstay of treatment as of now, which are very expensive and known to cause many side effects. It would be favourable if alternative treatment options like homeopathy are brought into limelight in the treatment of schizophrenia. Very sparse literature is available evaluating the utility of individualised homoeopathic medicine in the this condition.

Methods A 33-year-old woman presenting with symptoms of schizophrenia and under conventional medication was treated during a period of April 2019 to October 2020. Individualised homoeopathic medicine was prescribed as add-on therapy. Outcomes were assessed using Positive and Negative Syndrome Scale. Side effects of antipsychotics were assessed using Glasgow Antipsychotics Side-effects Scale. Modified Naranjo Criteria was used to assess whether the changes were likely to be associated with the homoeopathic intervention.

Results A beneficial result was obtained from individualised homoeopathic treatment. The antipsychotic medication was stopped within 9 months of treatment.

Conclusion More studies with large sample size are required to provide additional support to this study.

Keywords

homeopathy - add-on therapy - schizophrenia - Calc carb - Stramonium

Consent for Publication

Informed consent for publication was given by the mother of the patient. The signed document is confidential.


Authors' Contributions

S. Karunakara Moorthi was responsible for the preparation of manuscript. Radhika. P and Susu Pertin helped to assess the data and added to manuscript. N D Mohan was the consultant psychiatrist who prescribed the antipsychotics and supervised in filling the questionnaires.


Supplementary Material



Publication History

Article published online:
20 August 2022

© 2022. Thieme. All rights reserved.

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Joyce EM, Roiser JP. Cognitive heterogeneity in schizophrenia. Curr Opin Psychiatry 2007; 20 (03) 268-272
    CrossrefPubMedGoogle Scholar
  • 2 Lysaker PH, Vohs J, Minor KS. et al. Metacognitive deficits in schizophrenia: presence and associations with psychosocial outcomes. J Nerv Ment Dis 2015; 203 (07) 530-536
    CrossrefPubMedGoogle Scholar
  • 3 Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2 (05) e141
    CrossrefPubMedGoogle Scholar
  • 4 Vos T, Barber RM, Bell B. et al; Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386 (9995): 743-800
    CrossrefPubMedGoogle Scholar
  • 5 World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. World Health Organization; 2001
    Google Scholar
  • 6 Jablensky A. The 100-year epidemiology of schizophrenia. Schizophr Res 1997; 28 (2-3): 111-125
    CrossrefPubMedGoogle Scholar
  • 7 Brundtland GH. Mental health in the 21st century. Bulletin of the World Health Organization. Int J Public Health 2000; 78 (04) 411
    PubMedGoogle Scholar
  • 8 Gururaj G, Varghese M, Benegal V. et al. National Mental Health Survey of India, 2015–16: Prevalence, patterns and outcomes. Bengaluru, National Institute of Mental Health and Neuro Sciences, NIMHANS Publication No. 129. 2016
    PubMedGoogle Scholar
  • 9 Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry 2007; 64 (10) 1123-1131
    CrossrefPubMedGoogle Scholar
  • 10 Nordentoft M, Wahlbeck K, Hällgren J. et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One 2013; 8 (01) e55176
    CrossrefPubMedGoogle Scholar
  • 11 Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72 (12) 1172-1181
    CrossrefPubMedGoogle Scholar
  • 12 Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014; 13 (02) 153-160
    CrossrefPubMedGoogle Scholar
  • 13 Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 1990; 16 (04) 571-589
    CrossrefPubMedGoogle Scholar
  • 14 Miles CP. Conditions predisposing to suicide: a review. J Nerv Ment Dis 1977; 164 (04) 231-246
    CrossrefPubMedGoogle Scholar
  • 15 Charlson FJ, Ferrari AJ, Santomauro DF. et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull 2018; 44 (06) 1195-1203
    Google Scholar
  • 16 Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci 2010; 12 (03) 345-357
    CrossrefPubMedGoogle Scholar
  • 17 van Os J, Kapur S. Schizophrenia. Lancet 2009; 374 (9690): 635-645
    CrossrefPubMedGoogle Scholar
  • 18 Cooper C, Bebbington P, King M. et al. Why people do not take their psychotropic drugs as prescribed: results of the 2000 National Psychiatric Morbidity Survey. Acta Psychiatr Scand 2007; 116 (01) 47-53
    CrossrefPubMedGoogle Scholar
  • 19 Pai NB, Vella SC. Reason for clozapine cessation. Acta Psychiatr Scand 2012; 125 (01) 39-44
    CrossrefPubMedGoogle Scholar
  • 20 Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press, New York; . Press: 2000
    Google Scholar
  • 21 Hazra M, Noh S, Boon H, Taylor A, Moss K, Mamo DC. Complementary and alternative medicine in Psychotic disorders. J Complement Integr Med 2010; 7 (01) 1-16
    CrossrefPubMedGoogle Scholar
  • 22 Stevinson C, Ernst E. The desktop guide to complementary and alternative medicine: an evidence-based approach. J R Soc Med 2001; 94 (12) 650-651
    CrossrefPubMedGoogle Scholar
  • 23 Hoenders R. Integrative Psychiatry. Conceptual Foundation, Implementation and Effectiveness. Groningen University of Froningen; 2013: 212-212
    Google Scholar
  • 24 Rathbone J, Zhang L, Zhang M. et al. Chinese herbal medicine for schizophrenia: Cochrane systematic review of randomised trials. Br J Psychiatry 2007; 190 (05) 379-384
    CrossrefPubMedGoogle Scholar
  • 25 van der Greef J. Perspective: all systems go. Nature 2011; 480 (7378): S87
    CrossrefPubMedGoogle Scholar
  • 26 Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72 (05) 615-621
    CrossrefPubMedGoogle Scholar
  • 27 Mundewadi AA, Joshi DD, Arekar AS, Bakre GB, Mundewadi RA. A randomized, controlled, clinical trial of a herbal combination of aqueous extracts of Bacopa monnieri and Nardostachys jatamansi in schizophrenia, compared to standard anti-psychotic drug, olanzapine as an active control. Bombay Hosp J 2008; 50: 456-465
    PubMedGoogle Scholar
  • 28 Agarwal V, Abhijnhan A, Raviraj P. Ayurvedic medicine for schizophrenia. Cochrane Database Syst Rev 2007; (04) CD006867
    PubMedGoogle Scholar
  • 29 Jha A. Yoga therapy for schizophrenia. Acta Psychiatr Scand 2008; 117 (05) 397
    CrossrefPubMedGoogle Scholar
  • 30 Bangalore NG, Varambally S. Yoga therapy for schizophrenia. Int J Yoga 2012; 5 (02) 85-91
    CrossrefPubMedGoogle Scholar
  • 31 Lambert TJ, Castle DJ. Pharmacological approaches to the management of schizophrenia. Med J Aust 2003; 178 (S9): S57-S61
    CrossrefPubMedGoogle Scholar
  • 32 Janardhan NK, Gopinathan S, Pramanik MS. et al. Behavioral Disorders. Series I.: Clinical Research Studies; Clinical Research Studies. New Delhi: Central Council for Research in Homoeopathy; 2008: 1-14
    Google Scholar
  • 33 Oberai P, Gopinadhan S, Sharma A, Nayak C, Gautam K. Homoeopathic management of schizophrenia: a prospective, non-comparative, open-label observational study. Indian J Res Homoeopathy 2016; 10: 108-118
    CrossrefPubMedGoogle Scholar
  • 34 Fisher P, Dantas F, Rampes H. The safety of homeopathic products. J R Soc Med 2002; 95 (09) 474-475 , author reply 475–476
    PubMedGoogle Scholar
  • 35 Dantas F, Rampes H. Do homoeopathic medicines provoke adverse effects? A systematic review. Br Homeopath J 2000; 89 (01) 35-38
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 World Health Organization. The ICD-10, Classification of Mental and Behavioural Disorders. New Delhi: A.I.T.B.S. Publishers & Distributors; 2007
    Google Scholar
  • 37 Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13 (02) 261-276
    Google Scholar
  • 38 Glasgow Antipsychotic Side-effect Scale | Mental Health Partnerships. Accessed October 23, 2020. Accessed June 21, 2022 https://mentalhealthpartnerships.com/resource/glasgow-antipsychotic-side-effect-scale/
    PubMedGoogle Scholar
  • 39 van Haselen RA. Homeopathic clinical case reports: development of a supplement (HOM-CASE) to the CARE clinical case reporting guideline. Complement Ther Med 2016; 25: 78-85
    CrossrefPubMedGoogle Scholar
  • 40 A Systematic Review of Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia. Canadian Agency for Drugs and Technologies in Health. 2011 http://www.ncbi.nlm.nih.gov/books/NBK169697/ . Accessed June 21, 2022
    PubMedGoogle Scholar
  • 41 Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry 2013; 13: 50
    CrossrefPubMedGoogle Scholar